PRESS RELEASE:
Spectrum Names Dr. David Vigerust as Chief Scientific Officer
Leslie Titus Bryant, Director of Marketing & Brand
April 14th, 2021
| Leslie Titus Bryant, Director of Marketing & Brand April 14th, 2021 |
|---|
Spectrum Solutions announces David J. Vigerust, MS., PhD. has been named the company’s new Chief Scientific Officer. Dr. Vigerust has founded, led as CEO, and previously served as chief scientific officer for a number of progressive life science and advanced biotech companies. Much of Dr. Vigerust’s success is attributed to his superior logical and analytical approach in formulating innovative, non-linear industry solutions.
“Not only is Dr. Vigerust an award-winning and highly respected researcher and professor, he also has a deep foundational and highly practical scientific knowledge across multiple disciplines in biotechnology, medicine, and life science,” said Stephen Fanning, CEO of Spectrum Solutions.
In addition to his new role at Spectrum, Dr. Vigerust additionally holds teaching positions at Vanderbilt University Medical Center in the Department of Neurological Surgery as well as the University of Maryland, Eastern Shore School of Pharmacy. Throughout his career, he has developed several novel molecular diagnostic assays for the prediction of cardiovascular risk in patients with diabetes, infectious disease, and cancer.
Over the past 20 years, he has been the recipient of many research awards and honors including his selection as the 2016 TEDx presenting industry expert and speaker on the subject of precision medicine.
Dr. Vigerust received a bachelor’s degree in biology and chemistry from the University of Texas at El Paso, a master’s degree in microbiology and immunology from Texas Tech University in Lubbock, and a Ph.D. in cellular and molecular pathology from Vanderbilt University in Nashville, TN. Dr. Vigerust conducted post-doctoral research on viral glycosylation, host defense from influenza, and bacterial secondary infection in the Department of Infectious Disease at St. Jude Children’s Research Hospital. He completed a second post-doctoral fellowship at Vanderbilt University Medical School in the Department of Pediatric Infectious Disease in the area of molecular biology of respiratory viruses.
Dr. Vigerust has presented his research at national and international conferences and he is also an active editor and reviewer for several medical journals. He has been published in 26 peer-reviewed journals including Enhancement of Innate Immunity to COVID-19 with Natural Measures, published in Immunome Research in October 2020 and Microvascular disease confers additional risk to COVID-19 infection published in Medical Hypothesis in November 2020.
PRESS RELEASE:
Spectrum Names Dr. David Vigerust as Chief Scientific Officer
Leslie Titus Bryant, Director of Marketing & Brand
April 14th, 2021
| Leslie Titus Bryant, Director of Marketing & Brand April 14th, 2021 |
|---|
Spectrum Solutions announces David J. Vigerust, MS., PhD. has been named the company’s new Chief Scientific Officer. Dr. Vigerust has founded, led as CEO, and previously served as chief scientific officer for a number of progressive life science and advanced biotech companies. Much of Dr. Vigerust’s success is attributed to his superior logical and analytical approach in formulating innovative, non-linear industry solutions.
“Not only is Dr. Vigerust an award-winning and highly respected researcher and professor, he also has a deep foundational and highly practical scientific knowledge across multiple disciplines in biotechnology, medicine, and life science,” said Stephen Fanning, CEO of Spectrum Solutions.
In addition to his new role at Spectrum, Dr. Vigerust additionally holds teaching positions at Vanderbilt University Medical Center in the Department of Neurological Surgery as well as the University of Maryland, Eastern Shore School of Pharmacy. Throughout his career, he has developed several novel molecular diagnostic assays for the prediction of cardiovascular risk in patients with diabetes, infectious disease, and cancer.
Over the past 20 years, he has been the recipient of many research awards and honors including his selection as the 2016 TEDx presenting industry expert and speaker on the subject of precision medicine.
Dr. Vigerust received a bachelor’s degree in biology and chemistry from the University of Texas at El Paso, a master’s degree in microbiology and immunology from Texas Tech University in Lubbock, and a Ph.D. in cellular and molecular pathology from Vanderbilt University in Nashville, TN. Dr. Vigerust conducted post-doctoral research on viral glycosylation, host defense from influenza, and bacterial secondary infection in the Department of Infectious Disease at St. Jude Children’s Research Hospital. He completed a second post-doctoral fellowship at Vanderbilt University Medical School in the Department of Pediatric Infectious Disease in the area of molecular biology of respiratory viruses.
Dr. Vigerust has presented his research at national and international conferences and he is also an active editor and reviewer for several medical journals. He has been published in 26 peer-reviewed journals including Enhancement of Innate Immunity to COVID-19 with Natural Measures, published in Immunome Research in October 2020 and Microvascular disease confers additional risk to COVID-19 infection published in Medical Hypothesis in November 2020.
Access this press release on Business Wire
Bringing Baseball Back!
How you collect saliva makes a big difference
Increase workplace safety and build team confidence with simple and safe repeat testing programs supporting 100% accurate early detection and easy direct-to-user at-home options. Just ask Major League Baseball. See how our saliva collection system is credited for “bringing baseball back” and making Salt Lake “the league’s most important city”.
™/© 2020 MLB
Bringing Baseball Back!
How you collect saliva makes a big difference
Increase workplace safety and build team confidence with simple and safe repeat testing programs supporting 100% accurate early detection and easy direct-to-user at-home options. Just ask the Major League Baseball. See how our saliva collection system is credited for “bringing baseball back” and making Salt Lake “the league’s most important city”.
™/© 2020 MLB
About Spectrum Solutions®
Headquartered in Salt Lake City, Utah, Spectrum Solutions is dedicated to empowering complete wellness and bridging the gap between science and innovative healthcare solutions. Our stand-alone and fully integrated test-to-treat solutions support molecular diagnostics and DTC testing applications, advancing product development and accelerating go-to-market applications. Our single-source, end-to-end capabilities include a CAP/CLIA accredited molecular diagnostic laboratory, onsite compounding pharmacy, medical and non-medical product development, manufacturing, and fulfillment.
Spectrum Corporate Spokesman
Leslie Titus Bryant
Head of Marketing & Brand
admin@spectrumsolution.com
Media Contact
Tim Rush, Springboard5
801-208-1100
tim.rush@springboard5.com
About Spectrum Solutions®
Headquartered in Salt Lake City, Utah, Spectrum Solutions is dedicated to empowering complete wellness and bridging the gap between science and innovative healthcare solutions. Our stand-alone and fully integrated test-to-treat solutions support molecular diagnostics and DTC testing applications, advancing product development and accelerating go-to-market applications. Our single-source, end-to-end capabilities include a CAP/CLIA accredited molecular diagnostic laboratory, onsite compounding pharmacy, medical and non-medical product development, manufacturing, and fulfillment.
Spectrum Corporate Spokesman
Leslie Titus Bryant
Head of Marketing & Brand
admin@spectrumsolution.com
Media Contact
Tim Rush, Springboard5
801-208-1100
tim.rush@springboard5.com
Spectrum
in the News
Spectrum
in the News
Noninvasive
Saliva Diagnostics
This changes everything!
Saliva analysis looks at the cellular level, the biologically active compounds, making it a true representative of what is clinically relevant. Engineered to lead the saliva collection industry, the BioMAX™ delivers the safest and most robust biosample for the earliest detection and diagnosis of disease and infection.
Since 2020 and the COVID-19 pandemic, Spectrum’s saliva collection system not only introduced, it continues to expand the molecular diagnostics industry and its understanding of the opportunities saliva offers patients, providers, and laboratories.
- Pain-free, non-invasive, & safe
- Saliva contains the entire library of proteins, hormones, antibodies, and other molecular compounds measured in routine blood tests
- First EUA-authorized saliva collection device for COVID-19 testing
- No temperature-controlled storage or transport of collected biosamples
- A single saliva sample provides opportunity for multiple tests
- Months and years of post-collection stability with no degradation in sample efficacy (depending on the analyte)
- Maintain critical bio-sample consistency
- Mitigates any risk of viral infection throughout the testing process
- Delivers the highest levels of testing accuracy using qualified extraction chemistries
Noninvasive
Saliva Diagnostics
This changes everything!
Saliva analysis looks at the cellular level, the biologically active compounds, making it a true representative of what is clinically relevant. Engineered to lead the saliva collection industry, the BioMAX™ delivers the safest and most robust biosample for the earliest detection and diagnosis of disease and infection.
Since 2020 and the COVID-19 pandemic, Spectrum’s saliva collection system not only introduced, it continues to expand the molecular diagnostics industry and its understanding of the opportunities saliva offers patients, providers, and laboratories.
Outside-of-the-Box Thinking, Inside-of-the-Box Innovation
Anywhere from customized testing solutions to new medical science product innovations–we’re here to help.